Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) was downgraded by analysts at Northland Securities from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday, The Fly reports.
Separately, Cantor Fitzgerald lowered Opiant Pharmaceuticals to a “neutral” rating in a report on Tuesday.
Opiant Pharmaceuticals Trading Down 0.0 %
Shares of OPNT opened at $20.08 on Wednesday. The business’s 50-day moving average price is $11.92 and its 200-day moving average price is $12.04. Opiant Pharmaceuticals has a twelve month low of $7.34 and a twelve month high of $37.71. The stock has a market cap of $103.61 million, a PE ratio of -3.06 and a beta of 0.51. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.60.
Institutional Inflows and Outflows
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.